744 related articles for article (PubMed ID: 10950059)
21. [Preliminary report about the screening program for colorectal cancer by sequential fecal occult blood in Wuhan area for 4 years].
Lu ZM; Chen JG; Zhang YX; Wang Q; Xu J; Chen C; Yang R; Xiong F; Liu C; Peng XH
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep; 12(5):474-6. PubMed ID: 19742337
[TBL] [Abstract][Full Text] [Related]
22. Measuring the quality of colorectal cancer screening: the importance of follow-up.
Etzioni DA; Yano EM; Rubenstein LV; Lee ML; Ko CY; Brook RH; Parkerton PH; Asch SM
Dis Colon Rectum; 2006 Jul; 49(7):1002-10. PubMed ID: 16673056
[TBL] [Abstract][Full Text] [Related]
23. Colorectal cancer screening: physician attitudes and practices.
Taylor ML; Anderson R
WMJ; 2002; 101(5):39-43. PubMed ID: 12239980
[TBL] [Abstract][Full Text] [Related]
24. Predictors of colorectal screening in rural Colorado: testing to prevent colon cancer in the high plains research network.
Young WF; McGloin J; Zittleman L; West DR; Westfall JM
J Rural Health; 2007; 23(3):238-45. PubMed ID: 17565524
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the occult blood test in screening for colorectal neoplasms. A prospective study using flexible endoscopy.
Reilly JM; Ballantyne GH; Fleming FX; Zucker KA; Modlin IM
Am Surg; 1990 Mar; 56(3):119-23. PubMed ID: 2316930
[TBL] [Abstract][Full Text] [Related]
26. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
[TBL] [Abstract][Full Text] [Related]
27. A population-based, community estimate of total colon examination: the impact on compliance with screening for colorectal cancer.
Schoen RE; Weissfeld JL; Trauth JM; Ling BS; Hayran M
Am J Gastroenterol; 2002 Feb; 97(2):446-51. PubMed ID: 11866286
[TBL] [Abstract][Full Text] [Related]
28. Trends in screening for colorectal cancer--United States, 1997 and 1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Mar; 50(9):162-6. PubMed ID: 11393486
[TBL] [Abstract][Full Text] [Related]
29. Colonosopy screening and surveillance of colorectal cancer and polyps: physicians' knowledge.
Zbidi I; Hazazi R; Niv Y; Birkenfeld S
Isr Med Assoc J; 2007 Dec; 9(12):862-5. PubMed ID: 18210926
[TBL] [Abstract][Full Text] [Related]
30. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
[TBL] [Abstract][Full Text] [Related]
31. The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs.
El-Serag HB; Petersen L; Hampel H; Richardson P; Cooper G
Arch Intern Med; 2006 Nov; 166(20):2202-8. PubMed ID: 17101937
[TBL] [Abstract][Full Text] [Related]
32. Screening colonoscopy and fecal occult blood testing practice patterns: a population-based survey of gastroenterologists.
Rossi F; Sosa JA; Aslanian HR
J Clin Gastroenterol; 2008; 42(10):1089-94. PubMed ID: 18936643
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
[TBL] [Abstract][Full Text] [Related]
34. Colorectal cancer screening among first-degree relatives of colorectal cancer patients: benefits and barriers.
Mack LA; Cook LS; Temple WJ; Carlson LE; Hilsden RJ; Paolucci EO
Ann Surg Oncol; 2009 Aug; 16(8):2092-100. PubMed ID: 19479307
[TBL] [Abstract][Full Text] [Related]
35. Patient perceptions of stool-based DNA testing for colorectal cancer screening.
Schroy PC; Heeren TC
Am J Prev Med; 2005 Feb; 28(2):208-14. PubMed ID: 15710277
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
[TBL] [Abstract][Full Text] [Related]
37. Overcoming barriers to colorectal cancer screening tests.
Lachter J; Leska-Aharoni T; Warum D; Eliakim R
Isr Med Assoc J; 2008; 10(8-9):621-6. PubMed ID: 18847166
[TBL] [Abstract][Full Text] [Related]
38. Colorectal carcinoma screening procedure use among primary care patients.
Lafata JE; Williams LK; Ben-Menachem T; Moon C; Divine G
Cancer; 2005 Oct; 104(7):1356-61. PubMed ID: 16092119
[TBL] [Abstract][Full Text] [Related]
39. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
[TBL] [Abstract][Full Text] [Related]
40. Patterns and predictors of colorectal cancer test use in the adult U.S. population.
Seeff LC; Nadel MR; Klabunde CN; Thompson T; Shapiro JA; Vernon SW; Coates RJ
Cancer; 2004 May; 100(10):2093-103. PubMed ID: 15139050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
